Gastric Cancer

>

Latest News

PD-L1 Provides Valid Biomarker for Nivolumab/Chemo in Gastric Cancer
PD-L1 Provides Valid Biomarker for Nivolumab/Chemo in Gastric Cancer

February 28th 2024

In a discussion with Targeted Oncology, Michael Gibson, MD, PhD, discusses the benefits of using a patient’s PD-L1 combined positive score to determine if they are given nivolumab and chemotherapy to treat their gastric cancer.

Optimal Results: Neoadjuvant Durvalumab and Chemotherapy Drive  Improvement in Gastric/GEJ Cancers
Optimal Results: Neoadjuvant Durvalumab and Chemotherapy Drive Improvement in Gastric/GEJ Cancers

January 19th 2024

FDA Issues Complete Response Letter to Zolbetuximab BLA in GI Cancer
FDA Issues Complete Response Letter to Zolbetuximab BLA in GI Cancer

January 9th 2024

DisTinGuish Study of DKN-01 Completes Part C Enrollment in Gastric Cancer
DisTinGuish Study of DKN-01 Completes Part C Enrollment in Gastric Cancer

January 5th 2024

FDA Approves Pembrolizumab/Chemo for Gastric and GEJ Adenocarcinoma
FDA Approves Pembrolizumab/Chemo for Gastric and GEJ Adenocarcinoma

November 16th 2023

Video Series
Video Interviews

More News